search
Back to results

Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST) (NGS-IST)

Primary Purpose

Sexually Transmitted Infections (Not HIV or Hepatitis), Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Sponsored by
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Sexually Transmitted Infections (Not HIV or Hepatitis) focused on measuring Metagenomics Next-Generation-Sequencing (NGS), Sexually Transmitted Infections (STI), Pre-Exposure Prophylaxis (PrEP), Men who have Sex with Men (MSM)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years old
  • MSM
  • PrEP users
  • Acceptance of study constraints
  • Affiliated or beneficiary of a Social Security scheme or State Medical Aid
  • Signature of consent form to participate in the study

Exclusion Criteria:

  • Language barrier making questioning impossible.

Sites / Locations

  • Service des Maladies Infectieuses et Tropicales Hôpital Saint-AntoineRecruiting
  • Service des Maladies Infectieuses et Tropicales Hôpital TenonRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

12-months prospective multicenter longitudinal cohort with the biological samples collection.

Arm Description

This is a single-arm interventional study. After acceptance of the study (signature of the informed consent form), patients are included in the single-arm interventional study for a period of 12 months with follow-up visits every 3 months and intermediate visits in the case of the symptoms presence or sexual contacts with partners having STIs (corresponding to standard care for the PrEP users).

Outcomes

Primary Outcome Measures

To evaluate the performance of NGS metagenomic diagnosis of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (Ng) compared to reference techniques.
Sensitivity, specificity, positive and negative predictive values of NGS compared to reference techniques for Ng and Ct.

Secondary Outcome Measures

To evaluate the performance of the diagnosis by NGS of the other STIs compared to the reference techniques.
Sensitivity, specificity, positive and negative predictive values of NGS compared to reference techniques for other sexually transmitted infections (STIs).
Describe the epidemiology of circulating strains by molecular typing.
Total number of cases of Ct, Ng, agents not usually screened for in STI screening compared to the number of subjects at the time of their inclusion in the study cohort, with 95% confidence interval.
Estimate the incidence and describe the natural history of colonization by Mycoplasma genitalium (Mg).
Number of new cases Mycoplasma genitalium (Mg) compared to the number of subjects followed in the study cohort per month of follow-up.
Estimate the incidence of the appearance of Mycoplasma genitalium resistance under antibiotic selection pressure.
Number of new cases Mycoplasma genitalium (Mg) compared to the number of subjects followed in the study cohort per month of follow-up under antibiotic selection pressure.
Characterize circulating Neisseria gonorrhoeae (Ng) clones.
Total number of cases of circulating Neisseria gonorrhoeae (Ng) clones compared to the number of subjects at the time of their inclusion in the study cohort, with 95% confidence interval.
Characterize the circulating serotypes of Chlamydia trachomatis (Ct).
Total number of cases of circulating serotypes of Chlamydia trachomatis (Ct) compared to the number of subjects at the time of their inclusion in the study cohort, with 95% confidence interval.
Estimate the incidence of agents not usually screened for in STI screening (HSV-1, HSV-2, HPV, Mycoplasma hominis, Ureaplasma sp, Haemophilus ducreyi, Campylobacter sp, Shigella sp, Clostridium difficile, Entamoeba histolytica).
Number of new cases of agents not usually tested for in STI screening compared to the number of subjects followed in the study cohort per month of follow-up.
Determine the factors associated with STI events.
Hazard ratio of determinants (factors) associations with the STI cases incidence.

Full Information

First Posted
October 12, 2022
Last Updated
May 10, 2023
Sponsor
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Collaborators
ANRS, Emerging Infectious Diseases
search

1. Study Identification

Unique Protocol Identification Number
NCT05581160
Brief Title
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Acronym
NGS-IST
Official Title
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 11, 2022 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Collaborators
ANRS, Emerging Infectious Diseases

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of the study will be to assess the performance of the Next-Generation-Sequencing (NGS) diagnostics of Chlamydia trachomatis and Neisseria gonorrhoeae compared to reference techniques.
Detailed Description
Sexually Transmitted Infections (STIs) have become a major global public health problem and are among the most common infections. The increase antibiotic resistance, particularly in Neisseria gonorrhoeae and Mycoplasma genitalium, is of concern. Currently, the diagnosis of STIs is based on specific tests by pathogen, mainly by standard culture allowing an antibiotic susceptibility testing, gene amplification tests possibly allowing the search for resistance genes and serologies. Next-Generation-Sequencing (NGS) is based on the detection and analysis of any DNA and RNA present in the studied sample with a high degree of sensitivity, this method enables the precise identification of non-human sequences regardless its bacterial, viral or parasitologic origin, to detect resistance genes and to characterize the strains. The investigators propose to assess the performance of NGS for the diagnosis of STIs. A cohort of 332 PrEP users from Saint-Antoine and Tenon Hospitals will be followed for this purpose every 3 months during 1 year (including also the intermediate visits if needed in case of STIs symptoms). The main objective of the study will be to assess the performance of the NGS diagnostics of Chlamydia trachomatis and Neisseria gonorrhoeae compared to reference techniques. The secondary objectives will be (i) to evaluate the performance of the diagnosis by NGS of the other STIs compared to the reference techniques, (ii) to evaluate the interest and the sensitivity of a 3 sites pooled sample "urine, throat and rectum" and the swab sampling from the ulcer lesions in the case of the ulcerations presence for the diagnosis of STIs, (iii) to describe the natural history of colonization with Mycoplasma genitalium and the appearance of resistance or pressure of antibiotic selection and (iv) to evaluate the prevalence of agents not usually sought in screening for STI (HSV-1, HSV-2, Haemophilus ducreyi, Campylobacter sp, Shigella sp, Clostridioides difficile, Entamoeba histolytica). Improved diagnosis of STIs and resistance will allow a better patient management.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sexually Transmitted Infections (Not HIV or Hepatitis), Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
Keywords
Metagenomics Next-Generation-Sequencing (NGS), Sexually Transmitted Infections (STI), Pre-Exposure Prophylaxis (PrEP), Men who have Sex with Men (MSM)

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
12-months prospective multicenter longitudinal cohort with the biological samples collection.
Masking
None (Open Label)
Allocation
N/A
Enrollment
332 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
12-months prospective multicenter longitudinal cohort with the biological samples collection.
Arm Type
Experimental
Arm Description
This is a single-arm interventional study. After acceptance of the study (signature of the informed consent form), patients are included in the single-arm interventional study for a period of 12 months with follow-up visits every 3 months and intermediate visits in the case of the symptoms presence or sexual contacts with partners having STIs (corresponding to standard care for the PrEP users).
Intervention Type
Diagnostic Test
Intervention Name(s)
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Intervention Description
Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form). During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to: Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices. Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs. The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique. A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C.
Primary Outcome Measure Information:
Title
To evaluate the performance of NGS metagenomic diagnosis of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (Ng) compared to reference techniques.
Description
Sensitivity, specificity, positive and negative predictive values of NGS compared to reference techniques for Ng and Ct.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
To evaluate the performance of the diagnosis by NGS of the other STIs compared to the reference techniques.
Description
Sensitivity, specificity, positive and negative predictive values of NGS compared to reference techniques for other sexually transmitted infections (STIs).
Time Frame
12 months
Title
Describe the epidemiology of circulating strains by molecular typing.
Description
Total number of cases of Ct, Ng, agents not usually screened for in STI screening compared to the number of subjects at the time of their inclusion in the study cohort, with 95% confidence interval.
Time Frame
12 months
Title
Estimate the incidence and describe the natural history of colonization by Mycoplasma genitalium (Mg).
Description
Number of new cases Mycoplasma genitalium (Mg) compared to the number of subjects followed in the study cohort per month of follow-up.
Time Frame
12 months
Title
Estimate the incidence of the appearance of Mycoplasma genitalium resistance under antibiotic selection pressure.
Description
Number of new cases Mycoplasma genitalium (Mg) compared to the number of subjects followed in the study cohort per month of follow-up under antibiotic selection pressure.
Time Frame
12 months
Title
Characterize circulating Neisseria gonorrhoeae (Ng) clones.
Description
Total number of cases of circulating Neisseria gonorrhoeae (Ng) clones compared to the number of subjects at the time of their inclusion in the study cohort, with 95% confidence interval.
Time Frame
12 months
Title
Characterize the circulating serotypes of Chlamydia trachomatis (Ct).
Description
Total number of cases of circulating serotypes of Chlamydia trachomatis (Ct) compared to the number of subjects at the time of their inclusion in the study cohort, with 95% confidence interval.
Time Frame
12 months
Title
Estimate the incidence of agents not usually screened for in STI screening (HSV-1, HSV-2, HPV, Mycoplasma hominis, Ureaplasma sp, Haemophilus ducreyi, Campylobacter sp, Shigella sp, Clostridium difficile, Entamoeba histolytica).
Description
Number of new cases of agents not usually tested for in STI screening compared to the number of subjects followed in the study cohort per month of follow-up.
Time Frame
12 months
Title
Determine the factors associated with STI events.
Description
Hazard ratio of determinants (factors) associations with the STI cases incidence.
Time Frame
12 months

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
Men who have sex with men (MSM).
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old MSM PrEP users Acceptance of study constraints With or without Social Security scheme or State Medical Aid Signature of consent form to participate in the study Exclusion Criteria: Language barrier making questioning impossible.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Laure Surgers, MD
Phone
+33 1 71 97 01 19
Email
laure.surgers@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Hayette Rougier, MSc
Phone
+33 149 28 24 05
Email
hayette.rougier.sat@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karine Lacombe, Pr, PhD
Organizational Affiliation
IPLESP INSERM UMR-S1136
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Laure Surgers, MD
Organizational Affiliation
Service des Maladies Infectieuses et Tropicales Hôpital Saint-Antoine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Martin Siguier, MD
Organizational Affiliation
Service des Maladies Infectieuses et Tropicales et Tenon Hôpital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christophe Rodriguez, MD
Organizational Affiliation
INSERM U955 Eq18 CHU Henri Mondor
Official's Role
Study Director
Facility Information:
Facility Name
Service des Maladies Infectieuses et Tropicales Hôpital Saint-Antoine
City
Paris
ZIP/Postal Code
75012
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laure SURGERS, MD
Phone
+33 1 71 97 01 19
Email
laure.surgers@aphp.fr
Facility Name
Service des Maladies Infectieuses et Tropicales Hôpital Tenon
City
Paris
ZIP/Postal Code
75020
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Siguier, MD
Phone
+3301156017444/45
Email
martin.siguier@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Will be decided later by the scientific committee at the end of the study.
Citations:
PubMed Identifier
20643915
Citation
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum In: Science. 2011 Jul 29;333(6042):524.
Results Reference
background
PubMed Identifier
30539039
Citation
Chaix ML, Charreau I, Pintado C, Delaugerre C, Mahjoub N, Cotte L, Capitant C, Raffi F, Cua E, Pialoux G, Tremblay C, Meyer L, Molina JM; ANRS IPERGAY Study Group. Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial. Open Forum Infect Dis. 2018 Nov 8;5(11):ofy295. doi: 10.1093/ofid/ofy295. eCollection 2018 Nov.
Results Reference
background
PubMed Identifier
31127953
Citation
Deschamps O, Ortonne N, Hue S, Rodriguez C, Deschodt C, Hirsch G, Colin A, Gregoire L, Delfau-Larue MH, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S. Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. Br J Dermatol. 2020 Feb;182(2):355-363. doi: 10.1111/bjd.18166. Epub 2019 Aug 9.
Results Reference
background
PubMed Identifier
30125371
Citation
Fourati S, Rodriguez C, Hezode C, Soulier A, Ruiz I, Poiteau L, Chevaliez S, Pawlotsky JM. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology. 2019 Feb;69(2):513-523. doi: 10.1002/hep.30225. Epub 2019 Jan 5.
Results Reference
background
PubMed Identifier
32019895
Citation
Hernando Rovirola C, Spiteri G, Sabido M, Montoliu A, Gonzalez V, Casabona J, Cole MJ, Noori T, Unemo M. Antimicrobial resistance in Neisseria gonorrhoeae isolates from foreign-born population in the European Gonococcal Antimicrobial Surveillance Programme. Sex Transm Infect. 2020 May;96(3):204-210. doi: 10.1136/sextrans-2018-053912. Epub 2020 Feb 4.
Results Reference
background
PubMed Identifier
31178284
Citation
Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF, Boyd A, van Duijnhoven YTHP, Bruisten S, Oostvogel P, Davidovich U, Hogewoning A, Prins M, de Vries HJC; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam (H-TEAM) Initiative. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. Lancet HIV. 2019 Jul;6(7):e447-e455. doi: 10.1016/S2352-3018(19)30136-5. Epub 2019 Jun 6.
Results Reference
background
PubMed Identifier
28843576
Citation
Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, Boily MC. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017 Dec;17(12):1303-1316. doi: 10.1016/S1473-3099(17)30405-X. Epub 2017 Aug 23.
Results Reference
background
PubMed Identifier
29229440
Citation
Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bebear C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Dore V, Meyer L; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8.
Results Reference
background
PubMed Identifier
15472852
Citation
Nieuwenhuis RF, Ossewaarde JM, Gotz HM, Dees J, Thio HB, Thomeer MG, den Hollander JC, Neumann MH, van der Meijden WI. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis. 2004 Oct 1;39(7):996-1003. doi: 10.1086/423966. Epub 2004 Sep 8.
Results Reference
background
PubMed Identifier
31825501
Citation
Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, Rafael S, Anglade V, Falconer J, Ofori-Asenso R, Terris-Prestholt F, Hodges-Mameletzis I, Mayaud P. Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019 Dec 2;2(12):e1917134. doi: 10.1001/jamanetworkopen.2019.17134.
Results Reference
background
PubMed Identifier
31610037
Citation
Rodriguez C, Jary A, Hua C, Woerther PL, Bosc R, Desroches M, Sitterle E, Gricourt G, De Prost N, Pawlotsky JM, Chosidow O, Sbidian E, Decousser JW; Multidisciplinary Necrotizing Fasciitis Study Group. Pathogen identification by shotgun metagenomics of patients with necrotizing soft-tissue infections. Br J Dermatol. 2020 Jul;183(1):105-113. doi: 10.1111/bjd.18611. Epub 2019 Dec 2.
Results Reference
background
PubMed Identifier
32441621
Citation
Rodriguez C, Gricourt G, Ndebi M, Demontant V, Poiteau L, Burrel S, Boutolleau D, Woerther PL, Calvez V, Stroer S, Pawlotsky JM. Fatal Encephalitis Caused by Cristoli Virus, an Emerging Orthobunyavirus, France. Emerg Infect Dis. 2020 Jun;26(6):1287-1290. doi: 10.3201/eid2606.191431.
Results Reference
background
PubMed Identifier
28326064
Citation
Sitterle E, Rodriguez C, Mounier R, Calderaro J, Foulet F, Develoux M, Pawlotsky JM, Botterel F. Contribution of Ultra Deep Sequencing in the Clinical Diagnosis of a New Fungal Pathogen Species: Basidiobolus meristosporus. Front Microbiol. 2017 Mar 7;8:334. doi: 10.3389/fmicb.2017.00334. eCollection 2017.
Results Reference
background
PubMed Identifier
24982323
Citation
Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014 Jul;27(3):587-613. doi: 10.1128/CMR.00010-14.
Results Reference
background
PubMed Identifier
31896737
Citation
Van Praet JT, Steyaert S, Vandecasteele S, Van Den Bergh B, Mahieu H, De Buyser S, Grootaert V, Descheemaeker P, Reynders M. Mycoplasma genitalium acquisition and macrolide resistance after initiation of HIV pre-exposure prophylaxis in men who have sex with men. Sex Transm Infect. 2020 Sep;96(6):396-398. doi: 10.1136/sextrans-2019-054335. Epub 2020 Jan 2.
Results Reference
background
PubMed Identifier
31189036
Citation
Wilson MR, Sample HA, Zorn KC, Arevalo S, Yu G, Neuhaus J, Federman S, Stryke D, Briggs B, Langelier C, Berger A, Douglas V, Josephson SA, Chow FC, Fulton BD, DeRisi JL, Gelfand JM, Naccache SN, Bender J, Dien Bard J, Murkey J, Carlson M, Vespa PM, Vijayan T, Allyn PR, Campeau S, Humphries RM, Klausner JD, Ganzon CD, Memar F, Ocampo NA, Zimmermann LL, Cohen SH, Polage CR, DeBiasi RL, Haller B, Dallas R, Maron G, Hayden R, Messacar K, Dominguez SR, Miller S, Chiu CY. Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis. N Engl J Med. 2019 Jun 13;380(24):2327-2340. doi: 10.1056/NEJMoa1803396.
Results Reference
background
PubMed Identifier
24896819
Citation
Wilson MR, Naccache SN, Samayoa E, Biagtan M, Bashir H, Yu G, Salamat SM, Somasekar S, Federman S, Miller S, Sokolic R, Garabedian E, Candotti F, Buckley RH, Reed KD, Meyer TL, Seroogy CM, Galloway R, Henderson SL, Gern JE, DeRisi JL, Chiu CY. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med. 2014 Jun 19;370(25):2408-17. doi: 10.1056/NEJMoa1401268. Epub 2014 Jun 4.
Results Reference
background
PubMed Identifier
35307740
Citation
Surgers L, Chiarabini T, Royer G, Rougier H, Mercier-Darty M, Decre D, Valin N, Woerther PL, Decousser JW, Girard PM, Lacombe K, Boyd A. Evidence of Sexual Transmission of Extended-Spectrum beta-Lactamase-Producing Enterobacterales: A Cross-sectional and Prospective Study. Clin Infect Dis. 2022 Oct 29;75(9):1556-1564. doi: 10.1093/cid/ciac218.
Results Reference
background

Learn more about this trial

Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)

We'll reach out to this number within 24 hrs